Cannabis & Insomnia (PA)
Association Between Cannabis Use and Insomnia Medication in Pennsylvania: A Real-World Cohort Study
Adjusted Dosage Reduction
Adjusted gap representing a 0.49-unit reduction in monthly DDD ratio.
Benzodiazepine Drop
Lower dose intensity (0.79 vs 0.94) among benzodiazepine cohorts.
Under 30 Impact
The sharpest dose reduction observed across all age demographics.
Medication Reduction by Age Group
Age Interaction: Dose reductions are highly pronounced in younger cohorts and seniors, while middle-aged adults (45–59) showed negligible variance (Interaction b = 0.62).
Mean Monthly DDD Ratio Comparison
DDD (Defined Daily Dose) represents standard sleep medication quantity. Gap is highly statistically significant (p = 0.003) adjusted for covariates.
Demographic Profile
| Factor | Non-Users (n=1,564) | Cannabis Users (n=1,102) |
|---|---|---|
| Mean Age | 63.6 Years | 54.7 Years |
| Gender (Female) | 62.8% | 53.6% |
| Race (White) | 67.8% | 55.9% |
| Baseline DDD Ratio | 1.65 | 1.31 |
Gender & Dosage Associations
Key Observation on Product Form
While cannabis use was consistently associated with lower sedative prescriptions, the linear mixed-effects model found no statistically significant longitudinal association between specific product characteristics (THC dose, CBD dose, or THC:CBD ratio) and monthly sleep medication DDD ratios.
Study Conclusions
- • Substitution Evidence: Real-world point-of-sale data linked with EHRs reveals a strong and consistent association between medical cannabis use and reduced sleep medication intensity.
- • Benzodiazepine Reduction: Active cannabis users managed to decrease benzodiazepine doses by 16% on average.
- • Clean Demographics: Excluding secondary sleep disturbances from anxiety/depression diagnoses isolated the primary insomnia cohort.
Future Directions
- • Address Causality: Conduct prospective studies and controlled trials to better determine causality links.
- • Evaluate Long-Term Safety: Long-term follow-up studies are critical to monitor potential effects in older cohorts.
- • Standardize Formulations: Investigate dose-standardization patterns across varying commercial formats (flower, vapes, capsules).
Cannabis & Insomnia
The Role of Cannabis in Decreasing Dependence on Conventional Sleep Medications
This study explores whether the initiation of medical cannabis is associated with a measurable shift in conventional sleep medication usage among patients diagnosed with insomnia. Using linked dispensary transactions and electronic health record (EHR) data from Minnesota (2016-2022), the study tracks changes using the World Health Organization's Defined Daily Dose (DDD).
Overall Reduction
26.7%
Decrease in daily sleep medication dosage (DDD).
Benzodiazepine Drop
50.1%
Reduction in Benzodiazepine usage specifically.
Senior Benefit (65+)
60.0%
Reduction seen in patients over 65 years old.
DDD Ratio Shift
2.38 1.75
Average daily dose before vs. after cannabis.
Patient Demographics (Age)
Most patients fall within the middle-aged bracket, with the 35-50 group using higher baseline doses.
Medication Use: Before vs After Cannabis
Measured using Defined Daily Dose (DDD). Represents a 26.7% overall reduction.
Medication Reduction by Age Group
Older patients exhibited a much more pronounced reduction, mitigating major risks associated with conventional meds.
THC:CBD Ratios & Delivery Forms
THC:CBD Ratio Insights
| Category | Ratio(s) | Key Finding |
|---|---|---|
| Most Preferred | 19:1 | Used by 51% of patients in the study. |
| Most Effective |
4:1
20:1
1:1
|
Most associated with reducing sleep meds. Moderate CBD may provide necessary anxiolytic effects. |
Product Form Insights
Capsules (Most Effective)
Highest reduction in sleep meds. Higher bioavailability with slower onset but sustained, consistent effects ideal for maintaining sleep.
Gummies
Most frequently used by patients who had high dosages of traditional sleep medications at baseline.
Vapes & Tablets
Alongside capsules, these were the most common forms utilized by insomnia patients overall.
Impact on Benzodiazepines
High Risk MedsBenzodiazepines treat insomnia effectively but carry significant risks: tolerance, dependence, withdrawal, cognitive decline, and falls (especially in older adults).
| Medication Class | Reduction Post-Cannabis |
|---|---|
| Benzodiazepines |
50.17%
|
Dose-Dependent Effectiveness: Higher mg of THC correlated with higher daily doses of sleep meds, supporting existing literature that lower THC contents are often more effective for alleviating insomnia.
Older Adults: The most clinically significant finding is the 60% reduction in sleep meds for those >65. Cannabis represents a potential alternative to reduce the benzodiazepine burden in geriatrics.
Limitations: Small sample size (N=81), lack of a control group, and observational design means causality cannot be definitively established.
Future Research: Requires longitudinal studies in larger, diverse populations. Understanding the CBD anxiolytic effect vs THC stimulation, and tracking form-factor (capsules vs vapes) will be critical for informing clinical guidelines.
Cannabis & Anxiety
Medical Cannabis and Anti-Anxiety Medication: A Retrospective Analysis
Benzodiazepine shift
Reduction in daily dose compared to other agents.
Post-Cannabis
Baseline reduction in anti-anxiety medication.
Active use spike
Temporary DDD increase observed during active use.
Mean DDD Ratio (Dosage Trends)
Cannabinoid Profile Distribution
Demographics
| Metric | Finding |
|---|---|
| Gender Balance | 70% Female / 30% Male |
| Race (Majority) | 90% White (Caucasian) |
| Smoking Status | 90% Non-Smokers |
| Mean Age | 56 Years Old (SD: 11.5) |
Clinical Considerations
| Factor | Observation |
|---|---|
| THC Preference | 41% used 19:1 (High THC) |
| CBD Potential | 1:36 ratio showed lower DDD |
| Benzodiazepines | Primary candidate for reduction |
| Aqueous Solution | Associated with lowest DDD ratios |
Cannabis & Chronic Pain
Cannabis use and opioid prescriptions in chronic pain
Cancer Pain
Reduction in Morphine Milligram Equivalents (MME).
Neuropathic Pain
Reduction in opioid dosage post-cannabis.
Study Cohort
Ages 34–86
Opioid Reduction by Pain Type
Clinical Ratios
| Condition | Optimal THC:CBD Ratio |
|---|---|
| Neuropathic | 1:1 Balanced |
| Musculoskeletal | 19:1 THC-Dom |
| Cancer Pain | Mixed (1:1 & 19:1) |
Insight: Higher baseline MME intensity correlates with a clinical preference for high-THC formulations among successful reducers.
Study Conclusions
- • Objective Exposure: EHR data linked to transaction records provides objective usage patterns.
- • Opiod reduction: Significant MME reduction suggests cannabis is a viable pathway for reducing opioid reliance.
- • Patient profile: Specific pain types respond better to distinct THC:CBD ratios and delivery methods.
Next Steps
- • Control Groups: Implement matched cohorts to better isolate cannabis-specific effects from general shifts.
- • Gender Factors: Investigate gender-specific variance noted in neuropathic pain modulation responses.
- • Scaling: Larger studies are required to confirm systematic pattern observations.
Cannabis & Diabetes
Cannabis Use and Glycemic Control in Type 2 Diabetes
HbA1c
Adjusted percentage point reduction in HbA1c for cannabis users.
Circulatory
77% lower odds of circulatory complications compared to non-users.
BMI
Average lower baseline BMI in user group
Mean HbA1c Comparison
Odds Ratios for Complications
Relative to non-users (Reference = 1.0). All values adjusted for age, gender, and race.
THC:CBD Ratio Preference
Medication Interaction Analysis
Interpretation of Findings
The positive β-coefficients for Insulin and Metformin likely reflect disease severity (confounding by indication). Despite these associations, Cannabis use maintained a strong inverse relationship with HbA1c (-1.25), indicating its effect persists regardless of traditional antidiabetic medication burden.
Cannabis & Cardiovascular
Cannabis Use and Cardiovascular Risk: Impact of Product Type & Demographics
Younger Adult Risk
Greater odds of high lifetime CV risk in patients aged 20–39.
SBP
Mean reduction in Systolic Blood Pressure (mmHg) among cannabis users.
Lipid Profile
Lower LDL (mg/dL) and higher HDL among users (+6.91).
Lipid Profile Comparison (Users vs Non-Users)
Preferred Product Type by Age
CV Risk Marker Regression
| Variable | Impact of Cannabis Use | P-Value |
|---|---|---|
| Systolic BP | -4.28 mmHg | < 0.001 |
| Total Cholesterol | +7.10 mg/dL | < 0.001 |
| HDL (Good) | +6.91 mg/dL | < 0.001 |
| LDL (Bad) | -7.59 mg/dL | < 0.001 |
Adjusted for age, race, gender, and BMI.
Product Type Risk Variation
| Form (vs Flower) | Older (ASCVD Risk) | Younger (Lifetime Odds) |
|---|---|---|
| Vapes | +1.42% | 4.31x Risk |
| Edibles | -1.13% | 79% Lower |
| Tablets/Caps | -2.68% | 73% Lower |
| Topicals | -3.50% | 91% Lower |
Relative to flower use. Vaping is associated with the highest risk profiles across both age groups.
Cannabis & Chronic Pain (PA)
Medical Cannabis and Opioid Prescriptions in Chronic Pain: Pennsylvania
Individual Reduction
Mean monthly MME reduction per patient post-cannabis.
Seniors (60+) Impact
The largest reduction observed among age demographics.
Fentanyl Reduction
Drop in Fentanyl MME across PA, UT, and MN.
MME Reduction by Age Group (PA)
Fentanyl Dosage Tapering (Multi-State)
Reduction by Product Type
| Product Category | % Reduction | Potency Note |
|---|---|---|
| Shake / Trim / Lite | 88.4% | Highest observed |
| Flower | 77.5% | Common choice |
| Vape Products | 76.6% | High efficiency |
| Extracts | 75.9% | Concentrated |
THC:CBD Ratio Impact
Study Conclusions
- • Consistency: Reductions were consistent across genders (Female: 50.8%, Male: 48.3%).
- • Potency Link: Higher THC content was more strongly associated with successful opioid tapering.
Discussion & Limits
- • Fentanyl impact: 44.8% drop across three states represents high clinical significance for overdose prevention.
- • Real-World granularity: Linked POS and EHR data provides higher accuracy than self-report or claims data.
Cannabis & Chronic Pain (UT)
Cannabis and Opioid Prescriptions in Chronic Pain: Utah
Overall Reduction
Reduction in mean monthly MME (3832 to 1798).
Success Rate
Patients who showed a decrease in monthly MME.
Neuropathic Impact
The largest reduction observed among all pain types.
MME Reduction by Pain Category
Patient Demographics
| Metric | Cohort Profile |
|---|---|
| Mean Age | 49 Years (SD 14.4) |
| Gender | 54% Female / 45% Male |
| Ethnicity | 87% White, 1% Black, 0.5% Asian |
| Top Forms | Vapes (67.6%), Gummies (53.3%) |
Preferred Ratios
| Ratio (THC:CBD) | % of Reducers | Classification |
|---|---|---|
| 1:0 | 64% | THC-Dominant |
| 1:1 | 19% | Balanced |
| 0:1 | 16% | CBD-Dominant |
Critical Observations
Orofacial Pain: Outlier group showing a 20.6% increase in MME; requires further research into cannabis/headache pathophysiology.
Key Findings
- • Substitution Effect: Real-world transaction data suggests that 4 in 5 patients reduce opioid burden when incorporating medical cannabis.
- • THC Utility: High-THC formulations (1:0) appear to drive the majority of analgesic benefit and substitution for this population.
Discussion
- • Clinically meaningful: A reduction of 343 MME/month (adjusted model) suggests a shift in clinical behavior.
- • Regional trend: Utah findings align with previous Minnesota results, suggesting directional consistency across states.